What is the clinical evidence from this study?

Study design: Observational. Population: Suspected coronary artery disease (n=20). Intervention: Oral dipyridamole. Primary outcome: Pharmacokinetic disposition (time to maximum drug concentration).

What question did this study set out to answer?

To determine the pharmacokinetic disposition and time to peak plasma concentration of high-dose oral dipyridamole in patients undergoing thallium 201 myocardial perfusion imaging.

March 4, 1992Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Disposition of Oral Dipyridamole in Patients Undergoing Thallium 201 Myocardial Imaging

View Full Paper

Ask AI

Bookmark

Key result

A single 400-mg oral dose of dipyridamole yielded highly variable concentrations, with time to peak ranging from 0.5-2.5 hours and some patients having undetectable levels at injection.

Why the study?

What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?

Population

20 outpatients undergoing thallium 201 testing

Design

Cohort

Follow-up

4 hours

Authors

KSKathleen A. StringerEnvironmental Research Institute of Michigan JBJoseph M. BranconiMillard Fillmore Suburban Hospital RARalph AbadierMillard Fillmore Suburban Hospital

Discussion

Member takes

Overview

Variable dipyridamole exposure may limit thallium-201 imaging reliability in some patients; leaves open need for optimized protocols or alternatives in prospective studies.

Key Points

To determine the pharmacokinetic disposition and time to peak plasma concentration of high-dose oral dipyridamole in patients undergoing thallium 201 myocardial perfusion imaging.
Measured serial plasma dipyridamole concentrations in 20 outpatients following a single 400-mg oral dose administered prior to thallium 201 injection.
Evaluated hemodynamic parameters (systolic and diastolic blood pressure, heart rate) and compared drug concentrations between patients with positive and negative thallium scan results.
Time to peak plasma drug concentration ranged from 0.5 to 2.5 hours, and 2 out of 20 patients had undetectable dipyridamole levels at the time of thallium 201 injection.
Plasma concentrations displayed high variability ranging from 3% to 118%, with the area under the concentration-time curve (0–4 hours) spanning 2.3 to 2.9 microgram·hr/ml.
Circulating dipyridamole concentrations showed no direct correlation with changes in heart rate, systolic blood pressure, or diastolic blood pressure.

Study Design

Type

Observational (n=20)

Structured PICO

What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?

Population

20 outpatients undergoing thallium 201 testing evaluated for the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole.

Exposure

Single 400-mg oral dose of dipyridamole

Outcome

Pharmacokinetic disposition (serial concentrations and time to maximum drug concentration)surrogate

A single 400-mg oral dose of dipyridamole for thallium 201 imaging results in highly variable plasma concentrations, potentially limiting its diagnostic reliability in some patients.

Limitations

A small percentage of patients will not have detectable concentrations at the time of the first thallium 201 scan, possibly limiting the usefulness of this agent in conjunction with thallium scintigraphy in some patients.

Cite This Study

Stringer et al. (1992) conducted an observational in Suspected coronary artery disease (n=20). Oral dipyridamole was evaluated on Pharmacokinetic disposition (time to maximum drug concentration). A single 400-mg oral dose of dipyridamole yielded highly variable concentrations, with time to peak ranging from 0.5-2.5 hours and some patients having undetectable levels at injection.

synapsesocial.com/papers/6a93771ca475bae86f8bd470 https://doi.org/10.1002/j.1875-9114.1992.tb03613.x

View Full Paper

Ask AI

Bookmark

March 4, 1992Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Disposition of Oral Dipyridamole in Patients Undergoing Thallium 201 Myocardial Imaging

View Full Paper

Ask AI

Bookmark

Key result

A single 400-mg oral dose of dipyridamole yielded highly variable concentrations, with time to peak ranging from 0.5-2.5 hours and some patients having undetectable levels at injection.

Why the study?

What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?

Population

20 outpatients undergoing thallium 201 testing

Design

Cohort

Follow-up

4 hours

Authors

KSKathleen A. StringerEnvironmental Research Institute of Michigan JBJoseph M. BranconiMillard Fillmore Suburban Hospital RARalph AbadierMillard Fillmore Suburban Hospital

Discussion

Member takes

Overview

Variable dipyridamole exposure may limit thallium-201 imaging reliability in some patients; leaves open need for optimized protocols or alternatives in prospective studies.

Key Points

To determine the pharmacokinetic disposition and time to peak plasma concentration of high-dose oral dipyridamole in patients undergoing thallium 201 myocardial perfusion imaging.
Measured serial plasma dipyridamole concentrations in 20 outpatients following a single 400-mg oral dose administered prior to thallium 201 injection.
Evaluated hemodynamic parameters (systolic and diastolic blood pressure, heart rate) and compared drug concentrations between patients with positive and negative thallium scan results.
Time to peak plasma drug concentration ranged from 0.5 to 2.5 hours, and 2 out of 20 patients had undetectable dipyridamole levels at the time of thallium 201 injection.
Plasma concentrations displayed high variability ranging from 3% to 118%, with the area under the concentration-time curve (0–4 hours) spanning 2.3 to 2.9 microgram·hr/ml.
Circulating dipyridamole concentrations showed no direct correlation with changes in heart rate, systolic blood pressure, or diastolic blood pressure.

Study Design

Type

Observational (n=20)

Structured PICO

What is the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole in patients undergoing thallium 201 myocardial imaging?

Population

20 outpatients undergoing thallium 201 testing evaluated for the pharmacokinetic disposition of a single 400-mg oral dose of dipyridamole.

Exposure

Single 400-mg oral dose of dipyridamole

Outcome

Pharmacokinetic disposition (serial concentrations and time to maximum drug concentration)surrogate

A single 400-mg oral dose of dipyridamole for thallium 201 imaging results in highly variable plasma concentrations, potentially limiting its diagnostic reliability in some patients.

Limitations

A small percentage of patients will not have detectable concentrations at the time of the first thallium 201 scan, possibly limiting the usefulness of this agent in conjunction with thallium scintigraphy in some patients.

Cite This Study

synapsesocial.com/papers/6a93771ca475bae86f8bd470 https://doi.org/10.1002/j.1875-9114.1992.tb03613.x

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark